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ABSTRACT
DNA was extracted with a modified Qiagen DNA
Mini Kit method from 20 clinical samples and was
amplified by PCR using specific primers for the
T. gondii B1 gene. T. gondii was detected correctly
in 18 of the 20 clinical samples in < 5 h, with a
detection limit of two parasites ⁄ sample. The
results were in good agreement with those
obtained by a more complicated and time-con-
suming procedure involving two-step nested PCR
and either liquid hybridisation or colorimetric
detection using internal probes.
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The diagnosis of toxoplasmosis is based mainly
on the isolation and cultivation of parasite cells,
or on detection by serology, but these methods
are rather insensitive and time-consuming.
Nested PCR and PCR-ELISA have been used to
complement serodiagnosis [1–4], but although
these approaches are comparatively sensitive,
they are still complicated and time-consuming
[5–7]. In the present report, a simple PCR method
to detect Toxoplasma gondii-specific DNA directly
from clinical samples is described. The method
can be applied to amniotic fluid, vitreous fluid,
cerebrospinal fluid, blood samples and tissue
specimens.
The B1 gene of T. gondii is a 35-fold repetitive
gene, with 2214 nucleotides in each repeat, and is
highly conserved among Toxoplasma strains [8,9].
Primers Tg1 (5¢-AAAAATGTGGGAATGAAA-
GAG-3¢) and Tg2 (5¢-ACGAATCAACGGAACTG
TAAT-3¢) were designed and tested for specificity
in the BLASTN data base (http://www.ncbi.nlm.-
nih.gov/BLAST) and were predicted to be 100%
specific for the B1 gene. PCR with these primers
amplified a 469-bp DNA fragment of the B1 gene.
The PCR control primers used were b1 (5¢-AC-
CACCAACTTCATCCACGTTCACC-5¢) and b2
(5-CTTCTGACACAACTGTGTTCACTAGC-3¢);
these amplified a 140-bp DNA fragment of the
human b-globin gene [10]. Both reactions were
run simultaneously with the same temperature
protocol in parallel tubes in the same PCR
machine.
Twenty clinical samples, consisting of eight
amniotic fluid samples, two cerebrospinal fluid
samples, four vitreous fluid samples and six
tissue samples, were received from the Depart-
ment of Virology, Helsinki University Central
Hospital, Helsinki, Finland, and the Department
of Microbiology, Ullevaal University Hospital,
Oslo, Norway. All the samples were coded upon
receipt. The tissue samples were collected in
physiological saline in sterile tubes and stored at
) 70C immediately upon arrival until analysed.
The liquid samples were transferred to 2-mL
sterile microcentrifuge tubes and centrifuged at
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10 000 g for 10 min, after which the supernatant
was discarded. The microcentrifuge tubes with
pellets were stored at ) 70C until analysed. The
samples stored at ) 70C were thawed once before
DNA extraction. Total genomic DNA was extrac-
ted with the QIAamp DNA Mini Kit (Qiagen,
Valencia, CA, USA). The supplier’s protocol was
modified, as described below, for maximum
recovery of DNA.
In order to test the sensitivity of the method, a
suspension of T. gondii tachizoites was made and
the cells were counted by microscopy. Ten-fold
serial dilutions (106)101) of this suspension were
then made in 2-mL aliquots of amniotic fluid
and ⁄ or fresh human blood to yield concentrations
between 500 000 and 5 parasites ⁄mL.
The amniotic fluid suspension was centrifuged
at 10 000 g for 10 min, and the supernatant was
discarded. The pellet was resuspended in 180 lL
ATL buffer (supplied in the QIAamp DNA Mini
Kit), and the protocol recommended for tissue
samples was followed.
Blood samples were collected in Vacutainer
tubes (Becton Dickinson, Franklin Lakes, NJ,
USA) and then aliquoted (1 mL) into two 2-mL
microcentrifuge tubes. Blood cells were lysed by
the addition of an equal volume of lysis buffer A
(10 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 0.32 mM
saccharose and Triton X-100 1% v ⁄ v) [11]. The
lysates were vortexed briefly, incubated on ice for
5 min, and centrifuged at 8000 g for 3 min. The
supernatants were discarded and the pellet
resuspended in 0.1 mL lysis buffer A. Following
brief centrifugation, the supernatants from the
two tubes were pooled to give a total volume of
0.2 mL. The QIAamp tissue protocol was then
followed.
Tissue samples were cut into small pieces or
homogenised mechanically before suspension in
180 lL ATL lysis buffer (Qiagen). The QIAamp
tissue protocol was then followed. DNA was
eluted twice in elution buffer in a total volume of
100 lL. DNA from vitreous fluid and cerebrospi-
nal fluid was extracted using the same protocol as
described above for amniotic fluid.
A PCR master mix was prepared with 1 · PCR
Gold buffer, 200 lM each dNTP, 0.4 pmol of each
primer (Tg1 and Tg2), 1.5 mM MgCl2, and 1.25 U
of AmpliTaq Gold enzyme for each 50 lL reac-
tion. Reactions were preheated in a PTC-200 DNA
engine (MJ Research Inc., Waltham, MA, USA) for
10 min at 95C, followed by 35 cycles of 94C for
1 min, 52C for 30 s and 72C for 1 min, with a
final extension step at 72C for 7 min. Samples
(15 lL) of each reaction were analysed on agarose
1.8% w ⁄ v mini-gels by electrophoresis for 25 min
at 120 V, followed by staining with ethidium
bromide and visualisation under UV light. For
each sample, five reaction tubes were interpreted,
as indicated in Table 1.
The reproducible detection limit of the method
was two parasites ⁄ sample (Fig. 1). The sample
containing DNA equivalent to one parasite
genome yielded negative results in one of three
experiments.
The results obtained with the 20 clinical sam-
ples using the described method were in good
agreement with the results of analysis obtained by
nested PCR or PCR-ELISA using internal probes
in Oslo and Helsinki [6]. Nine of ten samples
reported positive in Oslo were also positive by
PCR. One sample, a piece of dark tissue (c. 5 mg),
was negative for T. gondii DNA in the present
study, but was described as an ‘uncertain’ posit-
ive in Oslo. This result could be caused by lack of
sufficient sample material. Similarly, nine of ten
Table 1. Interpretation of the five PCR results obtained for
each patient sample
1
Negative
control
2
Positive
control
3
b-globin
4
DNA:
10 l/reaction
5
DNA:
5 lL/reaction Interpretation
– + + + + Positive
– + + – – Negative
– + – – – Inhibitiona
– + – + – Inhibition of controla
aIn the case of PCR inhibition and ⁄ or inhibition of the control PCR, the template
DNA was repurified and ⁄ or diluted (1:10) before repeating the PCR.
M1234567
469-bp
Fig. 1. Sensitivity of detection of Toxoplasma PCR product
on agarose 1.8% w ⁄ v agarose gels. Lane 1: negative
control. Lane 2: equivalent to 32 genomes. Lane 3:
equivalent to 16 genomes. Lane 4: equivalent to eight
genomes. Lane 5: equivalent to four genomes. Lane 6:
equivalent to two genomes. Lane 7: equivalent to one
genome.
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samples from Helsinki were also positive by PCR.
One tissue sample (2–3 mg) was toxoplasma
DNA-positive in Helsinki, but negative in the
present study, again probably because of lack of
sufficient sample material. The sample volume is
important for a reproducible result. A minimum
of 2 mL of liquid sample or 10 mg of solid sample
was found to yield a reproducible result.
The lengths of the T. gondii-specific PCR prod-
uct (469 bp) and the b-globin inhibition control
(PCR) product (140 bp) were different. The effect
of this product-length difference on the PCR was
tested in a series of experiments, but no influence
on specificity or sensitivity was detected. In
addition, it was observed that the b-globin prim-
ers were capable of amplifying a specific PCR
product at annealing temperatures ranging from
48C to 64C.
It was concluded that the PCR method was a
rapid and sensitive approach to detecting T. gondii
DNA directly from clinical samples. Quantifica-
tion of DNA with real-time PCR experiments is
being used increasingly for the detection and
follow-up of various infections, and it would be
interesting to study the use of quantitative real-
time PCR for detection of T. gondii.
ACKNOWLEDGEMENTS
We would like to thank M. Holberg-Petersen for her generous
cooperation and provision of samples for this study, and A.
Magnusson for his skilful microscopic assistance.
REFERENCES
1. Joss AW, Chatterton JM, Evans R, Ho-Yen DO. Toxoplas-
ma polymerase chain reaction on experimental blood
samples. J Med Microbiol 1993; 38: 38–43.
2. Julander I, Martin C, Lappalainen M, Guy E, Isberg B,
Evengard B. Polymerase chain reaction for diagnosis of
cerebral toxoplasmosis in cerebrospinal fluid in HIV-pos-
itive patients. Scand J Infect Dis 2001; 33: 538–541.
3. Lappalainen M, Koskela P, Hedman K et al. Screening of
toxoplasmosis during pregnancy. Isr J Med Sci 1994; 30:
362–363.
4. Lappalainen M, Koskiniemi M, Hiilesmaa V et al.Outcome
of children after maternal primary Toxoplasma infection
during pregnancy with emphasis on avidity of specific
IgG. The Study Group. Pediatr Infect Dis J 1995; 14: 354–361.
5. Gross U, Roggenkamp A, Janitschke K, Heesemann J.
Improved sensitivity of the polymerase chain reaction for
detection of Toxoplasma gondii in biological and human
clinical specimens. Eur J Clin Microbiol Infect Dis 1992; 11:
33–39.
6. Guy EC, Pelloux H, Lappalainen M et al. Interlaboratory
comparison of polymerase chain reaction for the detection
of Toxoplasma gondii DNA added to samples of amniotic
fluid. Eur J Clin Microbiol Infect Dis 1996; 15: 836–839.
7. Montoya JG, Parmley S, Liesenfeld O, Jaffe GJ, Remington
JS. Use of the polymerase chain reaction for diagnosis of
ocular toxoplasmosis. Ophthalmology 1999; 106: 1554–1563.
8. Burg JL, Grover CM, Pouletty P, Boothroyd JC. Direct and
sensitive detection of a pathogenic protozoan, Toxoplasma
gondii, by polymerase chain reaction. J Clin Microbiol 1989;
27: 1787–1792.
9. Grover CM, Thulliez P, Remington JS, Boothroyd JC.
Rapid prenatal diagnosis of congenital Toxoplasma infec-
tion by using polymerase chain reaction and amniotic
fluid. J Clin Microbiol 1990; 28: 2297–2301.
10. Lee CN, Cavanagh HM, Lo ST, Ng CS. Human papillo-
mavirus infection in non-neoplastic uterine cervical dis-
ease in Hong Kong. Br J Biomed Sci 2001; 58: 85–91.
11. Gilbert RE, Gras L, Wallon M, Peyron F, Ades AE, Dunn
DT. Effect of prenatal treatment on mother to child
transmission of Toxoplasma gondii: retrospective cohort
study of 554 mother–child pairs in Lyon, France. Int
J Epidemiol 2001; 30: 1303–1308.
RESEARCH NOTE
Use of sodA sequencing for the
identification of clinical isolates of
coagulase-negative staphylococci
V. Sivadon1, M. Rottman1,
J.-C. Quincampoix1, V. Avettand1,
S. Chaverot1, P. de Mazancourt2, P. Trieu-
Cuot3 and J.-L. Gaillard1
Laboratoires de 1Microbiologie and 2Biochimie,
Hoˆpital Raymond Poincare´ (AP-HP), Garches
and 3Laboratoire Mixte Pasteur-Necker de
Recherche sur les Streptocoques et Streptococ-
cies and Unite´ INSERM 411, Faculte´ de Me´de-
cine Necker-Enfants Malades, Paris, France
ABSTRACT
This study evaluated the possible advantages
provided by a genotypic method over commer-
cially available biochemical systems for the iden-
tification of clinical isolates of coagulase-negative
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